{
  "source_file": "07_license_cytodyn.txt",
  "provider": "openai",
  "extraction": {
    "parties": {
      "raw_snippet": "This Commercialization and License Agreement (this \u201cAgreement\u201d) is made effective as of December 17, 2019 (the \u201cEffective Date\u201d) by and between\nVyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d).",
      "reasoning": "The introductory paragraph identifies the contracting parties by name and legal form (Vyera Pharmaceuticals, LLC and CytoDyn Inc.) as the parties to the Agreement.",
      "normalized_value": [
        "Vyera Pharmaceuticals, LLC",
        "CytoDyn Inc."
      ]
    },
    "contract_type": {
      "raw_snippet": "CytoDyn hereby grants to Vyera, and Vyera hereby accepts, an exclusive royalty-bearing license (or sublicense, as the case may be), under the CytoDyn Patents, the CytoDyn Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.",
      "reasoning": "The core economic substance is a grant of an exclusive, royalty-bearing license to Vyera to commercialize the licensed product in the defined field and territory. Although the title references commercialization, the primary legal mechanism is a license under CytoDyn Patents/Know-How to enable commercialization by Vyera.",
      "normalized_value": "License Agreement"
    },
    "agreement_date": {
      "raw_snippet": "This Commercialization and License Agreement (this \u201cAgreement\u201d) is made effective as of December 17, 2019 (the \u201cEffective Date\u201d) by and between\nVyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d).",
      "reasoning": "The contract opening states the Agreement is \"made effective as of December 17, 2019\" which is the explicit date the agreement was made/dated in the introductory paragraph.",
      "normalized_value": "2019-12-17"
    },
    "effective_date": {
      "raw_snippet": "This Commercialization and License Agreement (this \u201cAgreement\u201d) is made effective as of December 17, 2019 (the \u201cEffective Date\u201d) by and between\nVyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d).",
      "reasoning": "The same introductory sentence explicitly defines \"Effective Date\" as December 17, 2019.",
      "normalized_value": "2019-12-17"
    },
    "expiration_date": {
      "raw_snippet": "The term of this Agreement (\u201cTerm\u201d) shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall\nexpire on the last day of the Royalty Term.",
      "reasoning": "Section 11.1 defines the Term and states the Agreement expires on the last day of the Royalty Term; this is a relative expiration tied to the royalty term rather than a fixed calendar date.",
      "normalized_value": "commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall expire on the last day of the Royalty Term."
    },
    "governing_law": {
      "raw_snippet": "This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and\nconstrued in accordance with the laws of the State of New York, without giving effect to any choice of law principles that would result in the application\nof the laws of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions\ncontemplated by this Agreement",
      "reasoning": "Section 14.2 explicitly states the governing law as \"the laws of the State of New York\" for the Agreement and related disputes.",
      "normalized_value": "New York"
    },
    "notice_period": {
      "raw_snippet": "",
      "reasoning": "The contract contains various notice periods for termination (e.g., 180 days' notice for Vyera termination under Section 11.2(c)), but it does not include any clause that establishes an advance notice period to prevent an automatic renewal (i.e., there is no auto-renewal/renewal-prevention notice requirement). Therefore there is no \"notice period to terminate renewal\" to extract.",
      "normalized_value": ""
    },
    "renewal_term": {
      "raw_snippet": "",
      "reasoning": "The Agreement does not contain any automatic renewal clause or specified renewal term; the Term runs until the last day of the Royalty Term and contains termination provisions, but no renewal mechanics are specified.",
      "normalized_value": ""
    }
  },
  "usage": {
    "model": "gpt-5-mini-2025-08-07",
    "input_tokens": 36481,
    "output_tokens": 2309
  }
}